CLINICAL TRIAL: XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WIT

临床试验：XOLAIR 用于中度至重度特应性皮炎患者

• 批准号: 7717865
• 负责人: RICHARD Barry MOSS
• 金额: $ 0.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717865
• 关键词: Antibodies; Asthma; Atopic Dermatitis; Child; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Development; Dose; Food Hypersensitivity; Funding; Grant; Hay fever; Institution; Phase; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Wit; Xolair; anti-IgE; follow-up; omalizumab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study to determine the safety of an anti-IgE momoclonal antibody (Omalizumab, also called Xolair) in treating children with moderate to severe atopic dermatitis and food allergies. The dosing phase will last three to six months, and follow-up will continue for two yrs to determine if Xolair has any effect in reducing the development of hay fever and asthma.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究旨在确定抗IgE单克隆抗体（Omalizumab，也称为Xolair）治疗中重度特应性皮炎和食物过敏儿童的安全性。 给药阶段将持续三到六个月，随访将持续两年，以确定Xolair是否对减少花粉热和哮喘的发展有任何影响。